Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

US Army
Daiichi Sankyo
Queensland Health
UBS
Teva
Mallinckrodt
US Department of Justice
Deloitte
Citi
Fuji

Generated: December 12, 2017

DrugPatentWatch Database Preview

Wyeth Pharms Company Profile

« Back to Dashboard

What is the competitive landscape for WYETH PHARMS, and when can generic versions of WYETH PHARMS drugs launch?

WYETH PHARMS has thirty-seven approved drugs.

There are twenty-three US patents protecting WYETH PHARMS drugs on WYETH PHARMS drugs in the past three years.

There are three hundred and seventy-two patent family members on WYETH PHARMS drugs in sixty-seven countries and thirty-five supplementary protection certificates in twelve countries.

Summary for Wyeth Pharms

International Patents:372
US Patents:23
Tradenames:35
Ingredients:21
NDAs:37
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Exclusivity Expiration
Wyeth Pharms IncZOSYNpiperacillin sodium; tazobactam sodiumINJECTABLE;INJECTION050684-002Oct 22, 1993APRXYesYes► Subscribe► Subscribe► SubscribeY► Subscribe
Wyeth Pharms IncINDERALpropranolol hydrochlorideTABLET;ORAL016418-001Approved Prior to Jan 1, 1982DISCNYesNo► Subscribe► Subscribe► Subscribe► Subscribe
Wyeth PharmsOVRAL-28ethinyl estradiol; norgestrelTABLET;ORAL-28016806-001Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe► Subscribe
Wyeth Pharms IncPREMARINestrogens, conjugatedTABLET;ORAL004782-003Approved Prior to Jan 1, 1982RXYesNo► Subscribe► Subscribe► Subscribe► Subscribe
Wyeth Pharms PfizerDUAVEEbazedoxifene acetate; estrogens, conjugatedTABLET;ORAL022247-001Oct 3, 2013RXYesYes► Subscribe► Subscribe► SubscribeY► Subscribe
Wyeth Pharms IncLODINEetodolacCAPSULE;ORAL018922-003Jan 31, 1991DISCNYesNo► Subscribe► Subscribe► Subscribe► Subscribe
Wyeth Pharms IncZOSYNpiperacillin sodium; tazobactam sodiumINJECTABLE;INJECTION050684-001Oct 22, 1993APRXYesYes► Subscribe► Subscribe► SubscribeY► Subscribe
Wyeth Pharms IncLODINE XLetodolacTABLET, EXTENDED RELEASE;ORAL020584-002Oct 25, 1996DISCNYesNo► Subscribe► Subscribe► Subscribe► Subscribe
Wyeth Pharms IncZOSYNpiperacillin sodium; tazobactam sodiumINJECTABLE;INJECTION050684-004Oct 22, 1993APRXYesYes► Subscribe► Subscribe► SubscribeY► Subscribe
Wyeth Pharms IncNORPLANT SYSTEM IN PLASTIC CONTAINERlevonorgestrelIMPLANT;IMPLANTATION020088-001Dec 10, 1990DISCNNoNo► Subscribe► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Wyeth Pharms

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Wyeth Pharms IncEFFEXOR XRvenlafaxine hydrochlorideCAPSULE, EXTENDED RELEASE;ORAL020699-001Oct 20, 1997► Subscribe► Subscribe
Wyeth Pharms IncEFFEXOR XRvenlafaxine hydrochlorideCAPSULE, EXTENDED RELEASE;ORAL020699-001Oct 20, 1997► Subscribe► Subscribe
Wyeth Pharms IncPREMPROestrogens, conjugated; medroxyprogesterone acetateTABLET;ORAL-28020527-003Jan 9, 1998► Subscribe► Subscribe
Wyeth Pharms IncEFFEXOR XRvenlafaxine hydrochlorideCAPSULE, EXTENDED RELEASE;ORAL020699-004Oct 20, 1997► Subscribe► Subscribe
Wyeth Pharms IncPREMPROestrogens, conjugated; medroxyprogesterone acetateTABLET;ORAL-28020527-001Nov 17, 1995► Subscribe► Subscribe
Wyeth PharmsTRIPHASIL-21ethinyl estradiol; levonorgestrelTABLET;ORAL-21019192-001Nov 1, 1984► Subscribe► Subscribe
Wyeth Pharms IncLODINEetodolacCAPSULE;ORAL018922-003Jan 31, 1991► Subscribe► Subscribe
Wyeth Pharms IncPREMPHASE 14/14estrogens, conjugated; medroxyprogesterone acetateTABLET;ORAL-28020527-002Nov 17, 1995► Subscribe► Subscribe
Wyeth Pharms IncMYLOTARGgemtuzumab ozogamicinINJECTABLE;INJECTION021174-001May 17, 2000► Subscribe► Subscribe
Wyeth Pharms IncTRIPHASIL-28ethinyl estradiol; levonorgestrelTABLET;ORAL-28019190-001Nov 1, 1984► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for WYETH PHARMS drugs

Drugname Dosage Strength Tradename Submissiondate
desvenlafaxine succinate Extended-release Tablets 25 mg PRISTIQ 5/8/2015
desvenlafaxine succinateExtended-release Tablets50 mg and 100 mgPRISTIQ2/29/2012
piperacillin sodium and tazobactam sodiumFor Injection12 g/1.5 g per vial (pharmacy bulk)ZOSYN12/6/2011
levonorgestrel and ethinyl estradiolTablets0.09 mg/0.02 mgLYBREL10/5/2007
venlafaxine hydrochlorideExtended-release Tablets37.5 mg, 75 mg and 150 mgEFFEXOR XR5/3/2007
venlafaxine hydrochlorideTablets25 mg, 37.5 mg, 50 mg, 75 mg and 100 mgEFFEXOR11/3/2005
pantoprazole sodiumDelayed-release Tablets20 mg and 40 mgPROTONIX2/2/2004

Non-Orange Book Patents for Wyeth Pharms

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,835,729 2-phenyl-1-[4(2-aminoethoxy)-benzyl]-indoles as estrogenic agents► Subscribe
7,291,347Succinate salt of O-desmethyl-venlafaxine► Subscribe
7,247,6242-Phenyl-1-[4-(2-aminoethoxy)-benzyl]-indoles as estrogenic agents► Subscribe
6,127,404 Tissue selective compounds in the treatment of endometrial proliferation► Subscribe
6,924,281 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indoles as estrogenic agents► Subscribe
7,449,4552-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indoles as estrogenic agents► Subscribe
6,951,852 2-Phenyl-1-[4-(2-Aminoethoxy)-Benzyl]-Indoles as estrogenic agents► Subscribe
6,787,538 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indoles as estrogenic agents► Subscribe
6,291,451 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indoles as estrogenic agents► Subscribe
7,041,6632-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indoles as estrogenic agents► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Wyeth Pharms Drugs

Country Document Number Estimated Expiration
China1090018► Subscribe
South Africa200303593► Subscribe
Yugoslavia48263► Subscribe
MexicoPA03004548► Subscribe
China1250292► Subscribe
Poland211788► Subscribe
El Salvador1998000131► Subscribe
Czech Republic9700772► Subscribe
Germany60221642► Subscribe
Switzerland695185► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Wyeth Pharms Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C/GB02/037United Kingdom► SubscribePRODUCT NAME: TELMISARTAN, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, AND HYDROCHLOROTHIAZIDE; REGISTERED: UK EU/1/02/213/001 20020419; UK EU/1/02/213/002 20020419; UK EU/1/02/213/003 20020419; UK EU/1/02/214/004 20020419; UK EU/1/02/213/005 20020419; UK EU/1/02/213/006 20020419; UK EU/1/02/213/007 20020419; UK EU/1/02/213/008 20020419; UK EU/1/02/213/009 20020419; UK EU/1/02/213/010 20020419
C0009Belgium► SubscribePRODUCT NAME: IRBESARTAN / HYDROCHLOROTHIAZIDE; REGISTRATION NO/DATE: EU/1/98/086/001 19981015
/2015Austria► SubscribePRODUCT NAME: ETHINYLESTRADIOL UND EINE KOMBINATION VON LEVONORGESTREL UND ETHINYLESTRADIOL; NAT. REGISTRATION NO/DATE: 136021 20150224; FIRST REGISTRATION: SK 17/0017/15-S 20150211
C/GB96/056United Kingdom► SubscribePRODUCT NAME: PANTOPRAZOLE AND ITS SALTS, HYDRATES AND HYDRATES OF ITS SALTS; REGISTERED: SE SE12131 19940506; UK 04889/0010 19960604
323Luxembourg► SubscribePRODUCT NAME: LA COMBINAISON DE (A) DEXTROMETHORPHAN OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES, PRECURSEURS OU DERIVES , PAR EX. HYDROBROMURE DE DEXTROMETHORPHAN ET EN PARTICULIER HYDROBROMURE DE DEXTROMETHORPHAN MONOHYDRATE; ET(B) QUINIDINE OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES , PRECURSEURS OU DERIVES, PAR EX. SULFATE DE QUINIDINE ET EN PARTICULIER SULFATE DE QUINIDINE DEHYDRATE; FIRST REGISTRATION: 20130624
1214076/01Switzerland► SubscribePRODUCT NAME: DROSPIRENONE + ETHINYLESTRADIOL; REGISTRATION NUMBER/DATE: SWISSMEDIC 57946 13.06.2008
C0001France► SubscribePRODUCT NAME: ETHINYLESTRADIOL BETADEX CLATHRATE; NAT. REGISTRATION NO/DATE: NL 32343 20060710; FIRST REGISTRATION: NL - RVG 31781 20050804
C0032Belgium► SubscribePRODUCT NAME: PANTOPRAZOL. NATR. SESQUIHYDRAS PANTOPRAZOLE; NAT. REGISTRATION NO/DATE: 127 IS 98 F 3 19960222; FIRST REGISTRATION: SE 12131 19940506
C0062France► SubscribePRODUCT NAME: (A) DEXTROMETHORPHAN OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE, PAR EXEMPLE LE BROMHYDRATE DE DEXTROMETHORPHAN ET EN PARTICULIER LE MONOHYDRATE DE BROMHYDRATE DE DEXTROMETHORPHAN (B) QUINIDINE OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE, PAR EXEMPLE LE SULFATE DE QUINIDINE EN PARTICULIER LE DIHYDRATE DE SULFATE DE QUINIDINE; REGISTRATION NO/DATE: EU/1/13/833/001-003 20130626
156Luxembourg► SubscribePRODUCT NAME: LEVONORGESTREL ET ETHINYLESTRADIOL; FIRST REGISTRATION DATE: 20150211
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Daiichi Sankyo
Accenture
Chubb
Fuji
Colorcon
Moodys
McKinsey
McKesson
Fish and Richardson
US Army

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot